OncoZenge

Key Events for Fall 2025

OncoZenge will engage with investors, partners, and industry leaders at the following events:
 

Details for OncoZenge’s inaugural Capital Markets Day, including registration and agenda, will be announced soon.

Driving Innovation in Oral Pain Management

BupiZenge™, a novel oral lozenge formulation of bupivacaine, has the potential to redefine treatment for oral pain caused by oral mucositis, a debilitating condition affecting millions of cancer patients worldwide. In Phase 2 trials, BupiZenge™ delivered significantly superior pain relief compared to standard care, addressing a critical unmet need for effective, non-opioid therapies. With its Phase 3 program underway in Europe, OncoZenge is poised to transform patient outcomes while pursuing strategic partnerships for a future USA market entry.

“We are excited to connect with investors and partners this fall to share the transformative potential of BupiZenge,” said Stian Kildal, CEO of OncoZenge. “These events are a platform to highlight progress on our European Phase 3 program and commitment to build momentum towards a future introduction in the USA.”

Stay Connected
For more information on BupiZenge™ or to explore investment and partnership opportunities, visit www.oncozenge.se or contact:

Stian Kildal, CEO
Mobile: +46 76 115 3797
Email: stian.kildal@oncozenge.se

Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.

About OncoZenge
Headquartered in Stockholm, Sweden, OncoZenge is dedicated to developing better treatments for oral pain in conditions with significant unmet needs. BupiZenge™, its lead candidate, leverages decades of clinical experience with bupivacaine to offer a safe, effective, non-opioid and well-tolerated alternative to current therapies. OncoZenge is publicly traded on Nasdaq First North Growth Market (Ticker: ONCOZ).